-
Mashup Score: 2
A substudy of the phase 3 CheckMate-901 trial met its primary end points of overall survival and progression-free survival at final analysis.
Source: GU Oncology NowCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 1
Interview with David Henry MD
Source: PracticeUpdateCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Nivolumab Plus Brentuximab Vedotin an Option for Patients With Relapsed MGZL | ASH Clinical News | American Society of Hematology - 10 month(s) ago
Skip Nav Destination May 16, 2023 Anna Azvolinsky, PhD, is a freelance medical and science journalist based in New York City. The combination of nivolumab plus brentuximab vedotin has shown efficacy in a small cohort of patients…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
ASCO 2023, HCRN GU16-260 study, kidney cancer, renal cell carcinoma, genomics for renal cell carcinoma, nivolumab plus ipilimumab, whole exome sequencing (WES), SLAMF7, evaluating determinants of resistance to nivolumab monotherapy, CheckMate trials, somatic alterations in renal cancer.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Determinants of resistance to #nivolumab Monotherapy investigated through genomic and transcriptomic analysis of #RenalCellCarcinoma tumors from the HCRN GU16-260 study. Presented by @BraunMDPhD @YaleCancer. #ASCO23 written coverage by @RKSayyid @UofT > https://t.co/eQkhQUeNQH https://t.co/CsGneiyPkb
-
-
Mashup Score: 0Phase 3 SAPPHIRE Trial of Sitravatinib Misses Primary End Point in NSCLC - 11 month(s) ago
The primary end point of overall survival was not met in the phase 3 SAPPHIRE study of sitravatinib plus nivolumab in patients with advanced non-squamous non–small cell lung cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Dr Terence Friedlander explains safety and efficacy data from the CheckMate 247 trial, which led to the FDA approval of adjuvant nivolumab for patients with MIBC.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Nivolumab Combinations Improve Survival But Are Not Cost-Prohibitive in Advanced ESCC - 12 month(s) ago
An analysis of data from the CheckMate-648 trial sows that while adding nivolumab to either ipilimumab or chemotherapy for patients with advanced esophageal squamous cell carcinoma improves survival outcomes, their current price is not cost-effective for first-line treatment.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed data from the RELATIVITY-047 trial of nivolumab plus relatlimab for patients with metastatic melanoma. This is the second of 2 articles based on this event.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Nivolumab plus ipilimumab showed clinically meaningful overall survival results at 3 years among special populations of patients with metastatic non–small cell lung cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma – Full Text View.
Source: clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet
A substudy of the phase 3 CheckMate-901 trial has met its primary end points of overall survival and progression-free survival at final analysis, demonstrating a potential benefit of #nivolumab plus #cisplatin-based chemotherapy for mUC. Learn more: https://t.co/SczFgRIUD7 https://t.co/swyQtbaOHN